206 related articles for article (PubMed ID: 21527686)
21. The generic drug shortage.
Tidmarsh G
Clin Adv Hematol Oncol; 2012 Feb; 10(2):118-9. PubMed ID: 22402354
[No Abstract] [Full Text] [Related]
22. Taking aim at shortages. Order strengthens FDA's enforcement authority.
Lee J
Mod Healthc; 2011 Nov; 41(45):10. PubMed ID: 22106770
[No Abstract] [Full Text] [Related]
23. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
24. Meeting in the middle.
Nature; 2007 Jun; 447(7145):629. PubMed ID: 17554281
[TBL] [Abstract][Full Text] [Related]
25. Production of low cost AIDS drugs to continue in Brazil.
Reprod Health Matters; 2001 Nov; 9(18):178. PubMed ID: 11803899
[No Abstract] [Full Text] [Related]
26. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
27. US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.
Cohen D
BMJ; 2014 Nov; 349():g6593. PubMed ID: 25370846
[No Abstract] [Full Text] [Related]
28. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
29. Not everyone is perfct: about off-patent drugs.
Ann Oncol; 2001 Jun; 12(6):728. PubMed ID: 11484945
[No Abstract] [Full Text] [Related]
30. Obama takes action on drugs shortages.
Roehr B
BMJ; 2011 Nov; 343():d7158. PubMed ID: 22051520
[No Abstract] [Full Text] [Related]
31. [What drug companies actually do].
Tonby K
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
[No Abstract] [Full Text] [Related]
32. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
33. Reinventing an industry.
Mandavilli A
Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
[No Abstract] [Full Text] [Related]
34. Therapeutic-class wars--drug promotion in a competitive marketplace.
Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP
N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706
[No Abstract] [Full Text] [Related]
35. Eliminate cost-plus reimbursement for drugs.
Conti RM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):66. PubMed ID: 25129910
[No Abstract] [Full Text] [Related]
36. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
37. TRIPS: generic irony.
Howarth GR
Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
[No Abstract] [Full Text] [Related]
38. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
[TBL] [Abstract][Full Text] [Related]
39. Correcting Hatch-Waxman.
Fernandes M
Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
[No Abstract] [Full Text] [Related]
40. Best buy drugs: many common generics beat brand names.
Consum Rep; 2011 Mar; 76(3):24-7. PubMed ID: 21434454
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
